ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients

Transplantation

Volumn 81, Issue 3, 2006, Pages 463-468

  Gallon, Lorenzo ^a,d   Akalin, Enver ^b   Lynch, Patrick ^a   Rothberg, Laura ^a   Parker, Michele ^c   Schiano, Thomas ^b   Abecassis, Michael ^a   Murphy, Barbara ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Galter Pavilion 17 200 ^*  (United States)

Author keywords

Gene polymorphism; Liver transplantation; Nephrotoxicity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ANGIOTENSINOGEN; CALCINEURIN; CYCLOSPORINE; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RISK FACTORS; TACROLIMUS;

EID: 32844468742     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000185305.63759.d3     Document Type: Article

References (40)

1. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacal Ther 1996; 34: 515.
2. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089.
3. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
4. Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990; 10: 296.
5. Young EW, Ellis CN, Messana JM, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1991; 16: 1216.
6. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
7. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated endstage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63: 664.
8. Hornberger J, Best J, Geppert J, McClellan M. Risks and costs of endstage renal disease after heart transplantation. Transplantation 1998; 66: 1763.
9. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59.
10. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934.
11. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl JMed 2003; 349: 931.
12. Mervaala E, Lassila M, Vaskonen T, et al. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet. Blood Press 1999; 8: 49.
13. Perico N, Benigni A, Bosco E, et al. Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 1986, 25 Suppl 1:S83.
14. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660.
15. Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186.
16. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465.
17. Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43.
18. Beohar N, Damaraju S, Prather A, et al. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med 1995; 43: 275.
19. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343.
20. Hingorani AD, Brown MJ. A simple molecular assay for the C1166 variant of the angiotensin II type 1 receptor gene. Biochem Biophys Res Commun 1995; 213: 725.
21. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706.
22. Morris BJ, Monaghan JC, Perich R, et al. Genotypic influence on plasma dipeptidyl carboxypeptidase-1 activity in hypertensives. Clin Exp Pharmacol Physiol 1994; 21: 343.
23. Danser AH, Schalckamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92: 1387.
24. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786.
25. Jeunemaitre X, Inoue I, Williams C, et al. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 1997; 60: 1448.
26. Vleming LJ, van der Pijl JW, Lemkes HH, et al. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 1999; 51: 133.
27. Harden PN, Geddes C, Rowe PA, et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540.
28. van Essen GG, Rensma PL, de Zeeuw, D, et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347: 94.
29. Broekroelofs J, Stegeman CA, Navis G, et al. Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism? J Am Soc Nephrol 1998; 9: 2075.
30. Barocci S, Ginevri F, Valente U, et al. Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis. Transplantation 1999; 67: 534.
31. Vargas-Alarcon G, Hernandez-Pacheco G, Rodriguez-Perez JM, et al. Angiotensin-converting enzyme gene (ACE) insertion/deletion polymorphism in Mexican populations. Hum Biol 2003; 75: 889.
32. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10: 1136.
33. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol 1991; 2: S45.
34. Camara NO, Matos AC, Rodrigues DA, et al. Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity. Lancet 2001; 357: 856.
35. Khanna A, Plummer M, Bromberek C, et al. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62: 2257.
36. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141.
37. Paramesh AS, Roayaie S, Doan Y, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004; 18: 94.
38. Abdi R, Tran TB, Zee R, et al. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 2001; 72: 726.
39. Hadjadj S, Belloum R, Bouhanick B, et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 2001; 12: 541.
40. Kendrick EA, McVicar JP, Kowdley KV, et al. Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 1997; 63: 1287.